Skip to main content

DRIVING RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE

Objective


Antimicrobial resistance (AMR) is widespread. Its global human and economic burden is tremendous and increasing annually. Yet today only a few pharmaceutical companies retain active antibacterial drug discovery programmes. While the elaboration of antibiotics with novel mechanisms of action is scientifically complex, the chief challenge is diminishing incentives. Pre-market regulatory requirements and increased control on post-market access, use, and pricing of new antibiotics are strong deterrents to drug development. Meanwhile, healthcare payers are not currently prepared to reimburse antibiotics at prices that would support the cost of development.

Applied to antibiotics, a simple sales-based economic model contradicts the public health mandate to reduce their consumption in order to preserve their efficacy. Alternative models that can create incentives for the discovery of novel antibiotics and yet reconcile these incentives with responsible antibiotic use are long overdue.

The multidisciplinary and multi-stakeholder DRIVE-AB consortium composed of 16 public and 8 private partners from 12 countries will produce new models in a stepwise yet interconnected process. To achieve this objective, the DRIVE-AB consortium has put together a strong team that comprises both currently active researchers on the antibiotics problem and new researchers who can bring a fresh perspective as well as experience from other industries, economic specialties, and business cultures. The academic team has been enriched by EFPIA members and stakeholders from various backgrounds. With this diverse, yet closely tied team, DRIVE-AB will deliver fresh, sustainable solutions to this complex problem.

First, we will develop an evidence-based, consensus definition for “responsible antibiotic use,” which, with its standardised quality and quantity indicators, will provide the framework for all later steps. Next, data from surveillance systems, antibiotic prescription databases, and published literature will inform estimations of the present burden of antibiotic resistance from both clinical and economic perspectives across varying socioeconomic backdrops. Simulation models informed by these data as well as data from past and ongoing epidemics will estimate future public health needs and impact related to AMR, again in diverse socioeconomic settings. Together these constructs will allow for valuation models that will estimate the true value of existing and new antibiotics from the perspectives of patients, physicians, payers, and society as a whole. These, in turn, will inform the creation of alternative economic strategies and reward models that will promote and sustain the development of new antibiotics while simultaneously bolstering appropriate use of existing antibiotics. The most promising schemes will be presented to policymakers and other stakeholders with attendant implementation and risk-management strategies.

This ambitious project will not succeed if it is developed and championed merely by one sector of society, be it academia, “big pharma,” or public health. The robustness and applicability of the proposed alternative models will only be proportional to their level of input from all involved players. All work from beginning to end will be performed in close collaboration with the consortium’s stakeholder partners, which run the gamut from patients and clinical societies to small- and medium-sized enterprises, large pharmaceutical companies, healthcare payers, public health officials, and government officials. The DRIVE-AB consortium will dedicate considerable resources to this collaboration and to the final dissemination of information to policymakers and the wider public.

Overall, we are confident that the work of the DRIVE-AB consortium will have an immense impact. This is an unprecedented gathering of experts and stakeholders, led by renowned experts in various fields of medical, public health and economic sciences, to solve

Field of science

  • /social sciences/economics and business/economics/sustainable economy
  • /medical and health sciences/health sciences/public and environmental health
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance/antibiotic resistance

Call for proposal

IMI-JU-09-2013
See other projects for this call

Funding Scheme

JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)

Coordinator

ASTRAZENECA AB
Address
Vastra Maelarhamnen
151 85 Sodertaelje
Sweden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Principal investigator
Judith Hackett (Global Payer Evidence Director)
Administrative Contact
Eva Lindgren (Senior Director)

Participants (22)

UNIVERSITE DE GENEVE
Switzerland
EU contribution
€ 1 670 756
Address
Rue Du General Dufour 24
1211 Geneve
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Fabricio Jantarada (Mr.)
UNIVERSITEIT ANTWERPEN
Belgium
EU contribution
€ 74 770
Address
Prinsstraat 13
2000 Antwerpen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Anne Adams (Mrs)
STICHTING KATHOLIEKE UNIVERSITEIT
Netherlands
EU contribution
€ 280 445
Address
Geert Grooteplein Noord 9
6525 EZ Nijmegen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Andrea Kroon (mr.)
UPPSALA UNIVERSITET
Sweden
EU contribution
€ 933 080
Address
Von Kraemers Alle 4
751 05 Uppsala
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Gustav Sigeman (EU Research Officer)
Ursula Theuretzbacher
Austria
EU contribution
€ 351 640
Address
Eckpergasse
1180 Vienna
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ursula Theuretzbacher (n.a.)
British Society for Antimicrobial Chemotherapy
United Kingdom
EU contribution
€ 276 662
Address
Regent Place
B1 3NJ Birmingham
Administrative Contact
Tracey Kay Guise (Mrs)
THE ROYAL INSTITUTE OF INTERNATIONAL AFFAIRS
United Kingdom
EU contribution
€ 229 839
Address
Sint James S Square 10 Chatham House
SW1Y 4LE London
Activity type
Other
Administrative Contact
Claire Munoz Parry (Ms)
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Germany
EU contribution
€ 276 703
Address
Geschwister-scholl-platz
72074 Tuebingen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Evelina Tacconelli (Prof.)
FOLKEHELSEINSTITUTTET
Norway
EU contribution
€ 899 100
Address
Lovisenberggata 8
0456 Oslo
Activity type
Research Organisations
Administrative Contact
Christine Aardal (Ms.)
LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE
United Kingdom
EU contribution
€ 91 078
Address
Houghton Street 1
WC2A 2AE London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Milena Vasileva (Research Award Manager)
SVEUCILISTE U RIJECI, MEDICINSKI FAKULTET
Croatia
EU contribution
€ 24 300
Address
Brace Branchetta 20
51000 Rijeka
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Iva Križanec Ropac (dipl.iur.)
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Germany
EU contribution
€ 56 817
Address
Seminarstrasse 2
69117 Heidelberg
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Wiebke Tubbesing (Ms)
THE FOUNDATION FOR MEDICAL RESEARCH INFRASTRUCTURAL DEVELOPMENT AND HEALTH SERVICES NEXT TO THE MEDICAL CENTER TEL AVIV
Israel
EU contribution
€ 394 955
Address
Weizmann Street 6
64239 Tel Aviv
Activity type
Research Organisations
Administrative Contact
Galit Cohen (Dr.)
UNIVERSITE DE LORRAINE
France
EU contribution
€ 130 403
Address
Cours Leopold 34
54052 Nancy Cedex
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Serge BRIANCON (Professeur)
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.
United Kingdom
Address
Great West Road 980
TW89GS Brentford
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Sally Miles (Ms)
WAGENINGEN UNIVERSITY
Netherlands
EU contribution
€ 37 059
Address
Droevendaalsesteeg 4
6708 PB Wageningen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Oscar Van Rootselaar (Mr.)
UNIVERSITY OF STRATHCLYDE
United Kingdom
EU contribution
€ 572 380
Address
Richmond Street 16
G1 1XQ Glasgow
Activity type
Higher or Secondary Education Establishments
Administrative Contact
David McBeth (Dr)
ASTELLAS PHARMA EUROPE LTD
United Kingdom
Address
2000 Hillswood Drive
KT16 0RS Chertsey
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
CHRISTOPHER LONGSHAW (DR)
MERCK SHARP & DOHME CORP
United States
Address
One Merck Drive
08889 Whitehouse Station Nj
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Nicole Mahoney (Director, Global Regulatory Policy)
F. HOFFMANN-LA ROCHE AG
Switzerland
Address
Grenzacherstrasse 124
4070 Basel
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jason Hannon (Ph.D.)
PFIZER LIMITED
United Kingdom
Address
Ramsgate Road
CT13 9NJ Sandwich
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Olga Krylova (Dr)
SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
France
Address
Pierre Brossolette 1
91380 Chilly Mazarin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Nathalia MURILLO (Dr)